| 淡江大學 |
2006-08-01 |
Human Capital Measurement and Its Implications for Strategic Human Resource Development in the Public Sector: An Empirical Study in Taiwan
|
黃一峯; Huang, I-feng |
| 國立政治大學 |
2005-03 |
Human Capital Returns and Technological Change
|
莊奕琦 |
| 淡江大學 |
2010-12 |
Human Capital to Improve High-Tech Firm Performance
|
楊立人 |
| 元智大學 |
2006-11 |
Human capital, compensation scheme and performance of Biotech firms
|
Wen-Chung Guo (郭文忠); 夏侯欣榮; Wei-Jer Chien (簡偉哲) |
| 中華大學 |
2007 |
Human Capital, Organizational Learning, Network Resources and Organizational Innovativeness
|
徐聖訓; Hsu, Sheng-Hsun |
| 國立政治大學 |
2000-11 |
Human Capital,Export and Economic Growth:A Causality Analysis for Taiwan,1952-1995
|
莊奕琦; Chuang,Yih-chyi |
| 臺北醫學大學 |
1997 |
Human Carcinogenicity of Inorganic Arsenic
|
薛玉梅; Chen CJ; Hsueh YM; Chiou HY; Hsu YH; Chen SY; Horng SF; Liaw KF; Wu MM |
| 臺北醫學大學 |
1997 |
Human carcinogenicity of inorganic arsenic.
|
邱弘毅; Chen CJ;Hsueh YM;Chiou HY;Hsu YH;Chen SY;Horng SF; Liaw KF; Wu MM |
| 臺北醫學大學 |
1969-01 |
Human Cardiac Transplantation
|
劉和育 |
| 國立臺灣大學 |
2008-00 |
Human case of Rickettsia felis infection in Taiwan.
|
Tsai, K. H., H. Y. Lu, J. J. Tsai, S. K. Yu, J. H. Huang, and P. Y. Shu. |
| 臺大學術典藏 |
2022-03-30T08:21:32Z |
Human case of Rickettsia felis infection, Taiwan
|
KUN-HSIEN TSAI; Lu H.-Y.; Tsai J.-J.; Yu S.-K.; Huang J.-H.; Shu P.-Y. |
| 國立臺灣大學 |
2014 |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Chang, Ming-Chu; Jan, I-Shiow; Liang, Po-Chin; Jeng, Yung-Ming; Yang, Ching-Yao; Tien, Yu-Wen; Wong, Jau-Min; Chang, Yu-Ting; 鄭永銘; 詹一秀; 翁昭旼; 章明珠; 田郁文; 楊卿堯; 張毓廷; 梁博欽 |
| 臺大學術典藏 |
2018-09-10T14:52:54Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Jeng, Yung-Ming; Yang, Ching-Yao; Yang, Ching-Yao; I-SHIOW JAN; CHING-YAO YANG; Tien, Yu-Wen; Tien, Yu-Wen; Wong, Jau-Min; Chang, Yu-Ting; Chang, Yu-Ting; ?????]; ?????; Jeng, Yung-Ming; YU-WEN TIEN; Chen, Kuan-Chou; YU-TING CHANG; Liang, Po-Chin; Liang, Po-Chin; YUNG-MING JENG; Jan, I-Shiow; Chang, Ming-Chu;Jan, I-Shiow;Liang, Po-Chin;Jeng, Yung-Ming;Yang, Ching-Yao;Tien, Yu-Wen;Wong, Jau-Min;Chang, Yu-Ting; Chang, M.-C. and Jan, I.-S. and Liang, P.-C. and Jeng, Y.-M. and Yang, C.-Y. and Tien, Y.-W. and Wong, J.-M. and Chang, Y.-T.; Chang, Ming-Chu;Jan, I-Shiow;Liang, Po-Chin;Jeng, Yung-Ming;Yang, Ching-Yao;Tien, Yu-Wen;Wong, Jau-Min;Chang, Yu-Ting; 鄭永銘;詹一秀;翁昭旼;章明珠;田郁文;楊卿堯;張毓廷;梁博欽; 鄭永銘;詹一秀;翁昭旼;章明珠;田郁文;楊卿堯;張毓廷;梁博欽; Chang, Ming-Chu; PO-CHIN LIANG; Jan, I-Shiow |
| 臺大學術典藏 |
2020-02-20T02:57:02Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Chang M.-C.; Jan I.-S.; Liang P.-C.; Jeng Y.-M.; CHING-YAO YANG; Tien Y.-W.; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2020-02-20T06:53:11Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Chang M.-C.; Jan I.-S.; Liang P.-C.; Jeng Y.-M.; Yang C.-Y.; YU-WEN TIEN; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2020-03-06T08:25:06Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Liang P.-C.; YUNG-MING JENG; Yang C.-Y.; Tien Y.-W.; Wong J.-M.; Chang Y.-T.; Jan I.-S.; Chang M.-C. |
| 臺大學術典藏 |
2020-08-11T08:36:50Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Jeng Y.-M.; Yang C.-Y.; Tien Y.-W.; Wong J.-M.; Chang Y.-T.; PO-CHIN LIANG; Jan I.-S.; Chang M.-C. |
| 臺大學術典藏 |
2021-03-05T06:07:24Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
MING-CHU CHANG; Jan I.-S.; Liang P.-C.; Jeng Y.-M.; Yang C.-Y.; Tien Y.-W.; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2021-03-12T00:50:58Z |
Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis
|
Chang M.-C.; I-SHIOW JAN; Liang P.-C.; Jeng Y.-M.; Yang C.-Y.; Tien Y.-W.; Wong J.-M.; Chang Y.-T. |
| 國家衛生研究院 |
2006-10 |
Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival
|
Li, LY; Liu, MY; Shih, HM; Tsai, CH; Chen, JY |
| 臺大學術典藏 |
2019-08-30T01:08:15Z |
Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival
|
Li L.-Y;Liu M.-Y;Shih H.-M;Ching-Hwa Tsai;Chen J.-Y.; Li L.-Y; Liu M.-Y; Shih H.-M; CHING-HWA TSAI; Chen J.-Y. |
| 臺大學術典藏 |
2022-04-08T09:23:18Z |
Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival
|
Li L.-Y.; Liu M.-Y.; Shih H.-M.; CHING-HWA TSAI; Chen J.-Y. |
| 國立臺灣大學 |
2006 |
Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival.
|
Li, LY; Liu, MY; Shih, HM; Tsai, CH; Chen, JY. |
| 國立臺北護理健康大學 |
2006 |
Human cellular protein VRK2 specifically interacts with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival
|
劉玫英; Li, Long-Yuan;Liu, Mei-Ying;Shih, Hsiu-Ming;Tsai, Ching-Hwa;Chen, Jen-Yang |
| 中國醫藥大學 |
2006-10 |
Human cellular protein VRK2 specifically interacts with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival
|
李龍緣(Long-Yuan Li); (Mei-Ying Liu)*; (Hsiu-Ming Shih); (Ching-Hwa Tsai); (Jen-Yang Chen)* |
